ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Standards of Care and Future Directions in FL

Martin Dreyling

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Tazemetostat in Older Frail Adults With Follicular Lymphoma

Erin Mulvey

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Tazemetostat in R/R FL: Impact of EZH2 Mutational Status on PFS

Bruce D. Cheson

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

Treatment Landscape in Follicular Lymphoma

Mitchell Smith

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta

Tazemetostat Use in Community Settings for Follicular Lymphoma

Stephen M. Ansell